Long‐term outcomes of distant metastasis from differentiated thyroid carcinoma
Authors:
Open Access
- 26 September 2011
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 76 (3) , 439-447
Abstract
Summary: Background The aim of this study was to identify the prognostic factors of long‐term survival and optimal therapeutic protocol for patients with distant metastasis secondary to differentiated thyroid carcinoma (DTC).Methods A retrospective review of 1665 patients with DTC treated at a regional tertiary hospital in Taiwan between 1986 and 2010 was performed. Among them, 207 patients were found to have distant metastasis. For a long‐term outcome survey, 126 patients that had received at least 5 years (mean 9·6 ± 5·2 years) of follow‐up after the diagnosis of distant metastasis were analysed for this study. Prognostic factor analysis included age, sex, histology, disease stage, type of surgical procedure, site of metastatic foci, 131I avidity of tumour, thyroglobulin (Tg) level and accumulated therapeutic dose of radioiodine (RAI).Results The mean age at diagnosis of distant metastasis was 46·4 ± 17·2 years. The female‐to‐male ratio was 2·1:1. The 10‐ and 15‐year survival rates were 70·6% and 64·9%, respectively. The independent predictors of survival were younger age, surgical dissection of neck lymph nodes (LNs) and low TSH‐stimulated Tg level (600 mCi of 131I. The mean cumulative doses of 131I in both deceased and living patients were similar.Conclusion The prognosis of patients with distant metastasis from DTC within this study was found to be favourable. Survival may be improved by surgical dissection of neck LNs, but repeated 131I therapy >600 mCi is not advised unless there is a high probability that it would benefit the patient.Keywords
This publication has 32 references indexed in Scilit:
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- The Updated American Thyroid Association Guidelines for Management of Thyroid Nodules and Differentiated Thyroid Cancer: A Surgical PerspectiveThyroid®, 2009
- Prophylactic Lymph Node Dissection for Papillary Thyroid Cancer Less Than 2 cm: Implications for Radioiodine TreatmentThe Journal of Clinical Endocrinology & Metabolism, 2009
- The Importance of Age over Radioiodine Avidity as a Prognostic Factor in Differentiated Thyroid Carcinoma with Distant MetastasesThyroid®, 2009
- The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinomaSurgery, 2008
- Serum thyroglobulin determination in thyroid cancer patientsBest Practice & Research Clinical Endocrinology & Metabolism, 2008
- The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort StudyJournal of Nuclear Medicine, 2007
- Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancerSurgery, 2006
- Radioactive Iodine and the Salivary GlandsThyroid®, 2003
- Relationship Between Tumor Burden and Serum Thyroglobulin Level in Patients with Papillary and Follicular Thyroid CarcinomaThyroid®, 2002